<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03661411</url>
  </required_header>
  <id_info>
    <org_study_id>k（2018）22-1</org_study_id>
    <nct_id>NCT03661411</nct_id>
  </id_info>
  <brief_title>Antiplatelet vs R-tPA for Acute Mild Ischemic Stroke</brief_title>
  <acronym>ARAMIS</acronym>
  <official_title>Antiplatelet vs R-tPA for Acute Mild Ischemic Stroke: a Prospective, Random, Blinded Assessment of Outcome and Open Label Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute ischemic stroke (AIS) is one of common diseases with significant morbidity, mortality&#xD;
      and disability. A wide array of studies confirms that intravenous thrombolytic therapy with&#xD;
      alteplase can effectively improve the functional prognosis in acute ischemic stroke. Thus all&#xD;
      guidelines recommended the intravenous thrombolytic therapy with alteplase for acute ischemic&#xD;
      stroke within 4.5 hours from stroke onset.&#xD;
&#xD;
      Minor stroke is usually defined as NIHSS score ≤ 3 or 5，although it accounts for 1/2-2/3 of&#xD;
      AIS, the evidence of thrombolysis is insufficient. A study from Canada shows that 28.5% of&#xD;
      patients with minor stroke who have not receive rt-pa thrombolytic therapy are unable to walk&#xD;
      independently when discharged. Based on such a consideration,the PRISMS study further&#xD;
      compares the efficacy and safety of thrombolytic therapy with antithrombotic therapy in&#xD;
      patients with minor stroke. Unfortunately, the study has been early terminated due to the&#xD;
      sponsorship reason in 2018, with only 313 cases enrolled. The preliminary results shows that&#xD;
      there is no significant difference of the 90-day neurological function between the two&#xD;
      groups, while the safety of the treatment group with alteplase has a higher rate of&#xD;
      symptomatic intracranial hemorrhage. The patient receiving thrombolysis can not be given&#xD;
      antithrombolytic therapy within 24 hours even if the patient's condition has worsened, is&#xD;
      clinically more puzzling.&#xD;
&#xD;
      The CHANCE study in 2013 shows that the efficacy of aspirin with clopidogrel is superior to&#xD;
      aspirin alone with minor stroke (NIHSS &lt; 3) or TIA(ABCD2 &lt; 4). The POINT study in 2018&#xD;
      further confirmed the efficacy and safety of intensive antithrombotic therapy within 12 hours&#xD;
      of onset with minor stroke.&#xD;
&#xD;
      Based on the above discussion, this study aims to explore the efficacy and safety of aspirin&#xD;
      with clopidogrel vs alteplase in the treatment of acute minor stroke.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of mRS (0-1）</measure>
    <time_frame>90±7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of mRS (0-2）</measure>
    <time_frame>90±7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in NIH Stroke Scale score compared with baseline</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of early neurological improvement</measure>
    <time_frame>24 hours</time_frame>
    <description>more than 2 NIH Stroke Scale score decrease compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of early neurological deterioration</measure>
    <time_frame>7 days</time_frame>
    <description>more than 2 NIH Stroke Scale score increase (not result of cerebral hemorrhage) compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of stroke or other vascular events</measure>
    <time_frame>90±7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of death of any cause</measure>
    <time_frame>90±7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of symptomatic intracranial hemorrhage</measure>
    <time_frame>90±7 days</time_frame>
    <description>more than 4 NIHSS score increase caused by intracranial hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of any bleeding events</measure>
    <time_frame>90±7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">760</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Aspirin+ clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aspirin 100mg qd and clopidogrel 75mg（300mg in the first day）qd with a total of 10-14 days, then oral aspirin 100mg or clopidogrel 75mg qd lasting for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alteplase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous alteplase (0.9 mg/kg and maximal dose of 90 mg) was given, and followed by antithrombotic protocol 24 hours after thrombolysis based on clinical guideline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>100mg qd</description>
    <arm_group_label>Aspirin+ clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 75mg</intervention_name>
    <description>75mg（after first dose of 300mg）qd</description>
    <arm_group_label>Aspirin+ clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
    <description>Iv at 0.9 milligrams per kilogram (mg/kg)</description>
    <arm_group_label>Alteplase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient age ≥18 years;&#xD;
&#xD;
          2. Study treatment can be started within 4.5h;&#xD;
&#xD;
          3. Ischemic stroke confirmed by head CT or MRI;&#xD;
&#xD;
          4. NIHSS score ≤ 5, and ≤ 1 NIHSS score in single item scores such as vision, language,&#xD;
             neglect and single limb and no score in consciousness item;&#xD;
&#xD;
          5. Premorbid mRS ≤ 1;&#xD;
&#xD;
          6. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious neurological deficits before onset ( mRS ≥ 2)；&#xD;
&#xD;
          2. Obvious head injuries or strokes within 3 months；&#xD;
&#xD;
          3. Subarachnoid hemorrhage;&#xD;
&#xD;
          4. History of intracranial hemorrhage;&#xD;
&#xD;
          5. Intracranial tumor, arteriovenous malformation or aneurysm;&#xD;
&#xD;
          6. Intracranial or spinal cord surgery within 3 months;&#xD;
&#xD;
          7. Arterial puncture at a noncompressible site within the previous seven days;&#xD;
&#xD;
          8. Gastrointestinal or urinary tract hemorrhage within the previous 21 days;&#xD;
&#xD;
          9. Major surgery within 1 month;&#xD;
&#xD;
         10. Systolic pressure ≥180 mmHg or diastolic pressure ≥110 mmHg;&#xD;
&#xD;
         11. Blood glucose &lt; 50 mg/dl (2.7mmol/L);&#xD;
&#xD;
         12. Heparin therapy or oral anticoagulation therapy within 48 hours;&#xD;
&#xD;
         13. Platelet count of &lt;100,000/mm3 (This does not need to be verified prior to&#xD;
             randomization if clinical abnormality is not suspected);&#xD;
&#xD;
         14. Oral warfarin is being taken and INR&gt;1.6;&#xD;
&#xD;
         15. Abnormal APTT;&#xD;
&#xD;
         16. Pregnancy;&#xD;
&#xD;
         17. Neurological deficit after epileptic seizures;&#xD;
&#xD;
         18. Myocardial infarction within 3 months;&#xD;
&#xD;
         19. Cerebral infarction with definite anticoagulation indications, such as cerebral&#xD;
             infarction caused by cardiogenic embolism;&#xD;
&#xD;
         20. Oral administration is not allowed due to dysphagia;&#xD;
&#xD;
         21. allergy to study drugs;&#xD;
&#xD;
         22. Other serious illness that would confound the clinical outcome at 90 days;&#xD;
&#xD;
         23. Participating in other clinical trials within 3 months;&#xD;
&#xD;
         24. patients not suitable for this clinical studies considered by researcher;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huisheng Chen, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Neurology Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinhong Wang, Doctor</last_name>
    <phone>15309885658</phone>
    <phone_ext>024-28897512</phone_ext>
    <email>450341972@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu Cui, Master</last_name>
    <phone>18842398646</phone>
    <phone_ext>024-28897512</phone_ext>
    <email>314486939@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lin Tao</name>
      <address>
        <city>ShenYang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Tao, Master</last_name>
      <phone>86-24-28897499</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

